02:18:34 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-18 Bokslutskommuniké 2024
2024-11-19 Kvartalsrapport 2024-Q3
2024-08-20 Kvartalsrapport 2024-Q2
2024-06-07 Ordinarie utdelning CALMA B 0.00 SEK
2024-06-05 Årsstämma 2024
2024-05-21 Kvartalsrapport 2024-Q1
2024-02-20 Bokslutskommuniké 2023
2023-12-14 Extra Bolagsstämma 2023
2023-11-21 Kvartalsrapport 2023-Q3
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-23 Kvartalsrapport 2023-Q1
2023-05-17 Ordinarie utdelning CALMA B 0.00 SEK
2023-05-16 Årsstämma 2023
2023-02-21 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-09-22 Extra Bolagsstämma 2022
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-19 Ordinarie utdelning CALMA B 0.00 SEK
2022-05-17 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2022-02-23 Bokslutskommuniké 2021
2021-10-29 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-19 Ordinarie utdelning CALMA B 0.00 SEK
2021-05-18 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-12-23 Extra Bolagsstämma 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-20 Kvartalsrapport 2020-Q1
2020-05-15 Ordinarie utdelning CALMA B 0.00 SEK
2020-05-14 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-11-06 Extra Bolagsstämma 2019
2019-08-27 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning CALMA B 0.00 SEK
2019-05-09 Årsstämma 2019
2019-02-28 Bokslutskommuniké 2018
2018-11-26 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Calmark Sweden är verksamt inom medicinteknik. Bolaget specialiserar sig inom utveckling av diagnostiska verktyg riktade mot nyfödda barn. Tekniken utgår ifrån den egenutvecklade plattformen och används för analys de första veckorna efter födseln. Instrumentet används som biomarkör för att studera blodvärden. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget grundades under 2007 och har sitt huvudkontor i Karlstad.
2023-11-28 17:06:45

Calmark Sweden AB:s ("Calmark" or the "Company") preferential issue of units, with a subscription period that ended on November 10, 2023, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTU (paid subscribed unit) is December 4, 2023, and the stop day is December 6, 2023. The first day of trading in warrants of series TO 4 B is December 8, 2023.

In October/November 2023, Calmark carried out a rights issue which provided the Company with approximately SEK 8.56 million before issue costs. The rights issue has now been registered at the Swedish Companies Registration Office and the last day of trading in BTU is December 4, 2023, and the cut-off date is December 6, 2023. Shares and warrants of series TO 4 B are expected to be distributed to the VP account/depot on December 8, 2023.

After the Swedish Companies Registration Office's registration of the rights issue, the total number of shares in the Company amounts to 104 605 136 (of which 419 400 A-shares) and the share capital to SEK 10,460,513.60. In addition, there are 28,528,668 outstanding warrants of series TO 4 B. The first day of trading in warrants of series TO 4 B is December 8, 2023.

When the offset issue of shares to guarantors has been registered with the Swedish Companies Registration Office, the total number of shares will amount to 112,964,590 shares (of which 419,400 A shares) and the share capital will amount to SEK 11,296,459.00. If the issue of warrants of series TO 4 B to guarantors in the rights issue is approved by the extraordinary general meeting on December 14, 2023, and registered with the Swedish Companies Registration Office, there will be a total of 32,708,395 outstanding warrants of series TO 4 B.

Advisors

Sedermera Corporate Finance AB has in connection with the rights issue assisted Calmark as financial advisor, MAQS Advokatbyrå has assisted as legal advisor and Nordic Issuing AB as issuing agent.

For more information about the Rights Issue, please contact:

Sedermera Corporate Finance AB

Phone: +46 (0)40 615 14 10

E-mail: cf@sedermera.se

www.sedermera.se